Topical octapeptide marketed as an extended version of argireline for expression-line softening.
Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. Similar proposed mechanism to argireline (SNARE interference) with two additional N-terminal residues.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Cosmetic ingredient.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
No indexed ClinicalTrials.gov studies for SNAP-8. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.
No citations indexed yet.